Trial Profile
RESOLUTE International : Prospective, multi-center, observational registry to evaluate the safety and clinical performance of the Endeavor Resolute Zotarolimus-Eluting Coronary Stent System in a real-world patient population requiring stent implantation by assessing the rates of cardiac death and MI. - Resolute International.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Aug 2016
Price :
$35
*
At a glance
- Drugs Zotarolimus (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Registrational; Therapeutic Use
- Acronyms R-Int; RESOLUTE-Int; RESOLUTE-International
- 13 Dec 2012 New source identified and integrated (Clinical Trials Registry - India - CTRI2009-091-000416).
- 05 Dec 2011 Company added as trial sponsor as reported by ClinicalTrials.gov.
- 05 Dec 2011 Planned End Date changed from 1 Apr 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.